Department of Diagnostic Imaging, Sheba Medical Center, Tel Hashomer, Israel, and Sackler Medical School, Tel Aviv University, Tel Aviv, Israel.
Sheba Talpiot Medical Leadership Program, Tel Hashomer, Israel, and Sackler Medical School, Tel Aviv University, Tel Aviv, Israel.
Hum Vaccin Immunother. 2022 Nov 30;18(5):2065814. doi: 10.1080/21645515.2022.2065814. Epub 2022 Apr 26.
We aimed at assessing the published literature on different prophylactic screening and vaccination options in inflammatory bowel disease (IBD) patients between 1980 and 2020. Special attention was attributed to latest data assessing covid-19 vaccinations.
We have queried PubMed for all available IBD-related entries published during 1980-2020. The following data were extracted for each entry: PubMed unique article ID (PMID), title, publishing journal, abstract text, keywords (if any), and authors' affiliations. Two gastrointestinal specialists decided by consensus on a list of terms to classify entries. The terms belonged to four treatment groups: opportunistic infections, prophylactic screening, prophylactic vaccinations/treatment, and routine vaccines. Annual trends of publications for the years 1980-2020 were plotted for different screening, vaccinations and infection types. Slopes of publication trends were calculated by fitting regression lines to the annual number of publications.
Overall, 98,339 IBD entries were published between 1980 and 2020. Of those, 7773 entries belonged to the investigated groups. Entries concerning opportunistic infections showed the sharpest rise, with 19 entries and 1980 to 423 entries in 2020 (slope 11.3, p < .001). Entries concerning prophylactic screening rose from 10 entries in 1980 to 204 entries in 2020 (slope 5.4, p < .001). Both entries concerning prophylactic vaccinations/treatments and routine vaccines did not show a significant rise (slope 0.33 and slope 0.92, respectively). During the COVID 19 pandemic, a total of 44 publications were identified. Of them, 37 were relevant to vaccines and immune reaction. Nineteen publications (51%) were guidelines/recommendations, and 14 (38%) assessed immune reaction to vaccination, most of them (11, 61%) to mRNA vaccines.
During the past two decades, along with a rapid increase in biologic therapy, publications regarding opportunistic infections and prophylactic screening increased in a steep slope compared to the two decades in the pre-biologic area. During the COVID-19 pandemic, most publications included vaccination recommendations and guidelines and only 38% included real-world data assessing reaction to vaccinations. More research is needed.
评估 1980 年至 2020 年间发表的有关炎症性肠病（IBD）患者不同预防性筛查和疫苗接种选择的文献。特别关注最新评估 COVID-19 疫苗接种的数据。
我们在 PubMed 上查询了 1980 年至 2020 年间发表的所有与 IBD 相关的文章。为每个条目提取了以下数据：PubMed 唯一文章 ID（PMID）、标题、出版期刊、摘要文本、关键字（如果有）和作者的所属机构。两位胃肠病专家通过共识决定了一组用于分类条目的术语。这些术语属于四个治疗组：机会性感染、预防性筛查、预防性疫苗接种/治疗和常规疫苗。对 1980-2020 年不同筛查、疫苗接种和感染类型的出版物进行了年度趋势图绘制。通过拟合年度出版物数量的回归线来计算出版物趋势的斜率。
总体而言，1980 年至 2020 年间共发表了 98339 篇 IBD 文章。其中，7773 篇属于调查的组别。有关机会性感染的文章数量增长最为明显，从 19 篇增加到 2020 年的 423 篇（斜率 11.3，p < 0.001）。关于预防性筛查的文章从 1980 年的 10 篇增加到 2020 年的 204 篇（斜率 5.4，p < 0.001）。关于预防性疫苗接种/治疗和常规疫苗的文章数量均未呈现明显增长（斜率分别为 0.33 和 0.92）。在 COVID-19 大流行期间，共确定了 44 篇文章。其中，37 篇与疫苗和免疫反应有关。19 篇（51%）为指南/建议，14 篇（38%）评估了疫苗接种后的免疫反应，其中大多数（11 篇，61%）为 mRNA 疫苗。
在过去的二十年中，随着生物治疗的迅速发展，与机会性感染和预防性筛查相关的出版物呈陡峭上升趋势，与生物治疗前二十年相比增长更为显著。在 COVID-19 大流行期间，大多数出版物包括疫苗接种建议和指南，只有 38%的出版物包括评估疫苗接种反应的真实世界数据。需要进一步的研究。
